Log in or register to see all Alerts
New HTA Decisions in England
December 2021
Drug name
SAXENDA® (liraglutide)
Novo Nordisk
Decision date
Therapeutic area
Diabetes and other endocrinal, nutritional and metabolic conditions
Therapeutic sub area
Not recommended
Terminated appraisal
Decision Detail
NICE is unable to make a recommendation about the use in the NHS of liraglutide for managing obesity in people aged 12 to 17 years. This is because Novo Nordisk does not intend to provide an evidence submission for the appraisal. Novo Nordisk considers that there is not enough evidence to provide an evidence submission for this appraisal. NICE will review the position if the company decides that it wants to make an evidence submission.